A comprehensive view of Daiichi Sankyo Company Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca and Daiichi Sankyo's drug, Enhertu, successfully slows tumor progression in Phase 3 trial for ultralow HER2 breast cancer patients, possibly expanding the drug's use; the trial to continue to assess survival and other study measures
Published: April 29, 2024 by BioPharma Dive
J&J seeks FDA approval for Tremfya guselkumab to treat adults with moderate to severe active ulcerative colitis, UK approves Daiichi Sankyo’s oral acute myeloid leukemia drug Vanflyta; UK also approves Pfizer’s Velsipity etrasimod
Published: March 12, 2024 by FiercePharma
Daiichi Sankyo to invest US$1.08B to expand its production and development site in Pfaffenhofen, Germany, to enhance its capabilities in the antibody-drug conjugate field; the project is expected to create 350 jobs by 2030
Published: February 21, 2024 by FiercePharma
FDA grants priority review to AstraZeneca and Daiichi Sankyo's sBLA for Enhertu; drug could be the first HER2-directed treatment and antibody drug conjugate to treat adult patients with unresectable or metastatic HER2-positive solid tumors
Published: February 05, 2024 by Contify Life Science News
Daiichi Sankyo raises sales forecast for AstraZeneca-partnered Enhertu to US$2.6B due to positive developments outside the US, despite lowering the drug's sales estimate in the US to US$1.58B
Published: February 05, 2024 by FiercePharma

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count